Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants.
Oncolytic viruses
dendritic cells
infection
vesicular stomatitis virus
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
16
10
2021
Statut:
epublish
Résumé
Oncolytic viruses (OVs) can eradicate tumor cells and elicit antitumor immunity. VSV-GP, a chimeric vesicular stomatitis virus (VSV) with the glycoprotein (GP) of the lymphocytic choriomeningitis virus, is a promising new OV candidate. However, the interaction of VSV-GP with host immune cells is not fully understood. Dendritic cells (DCs) are essential for inducing efficient antitumor immunity. Thus, we aimed to investigate the interaction of VSV-GP with different murine and human DCs subsets in direct comparison to the less cytopathic variant VSV-dM51-GP and wild type VSV. Immature murine bone marrow-derived DCs (BMDCs) were equally infected and killed by VSV and VSV-GP. Human monocyte-derived DCs (moDCs) were more permissive to VSV. Interestingly, VSV-dM51-GP induced maturation instead of killing in both BMDCs and moDCs as well as a pronounced release of pro-inflammatory cytokines. Importantly, matured BMDCs and moDCs were no longer susceptible to VSV-GP infection. Mouse splenic conventional DC type 1 (cDC1) could be infected
Identifiants
pubmed: 34484872
doi: 10.1080/2162402X.2021.1959140
pii: 1959140
pmc: PMC8409795
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1959140Informations de copyright
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
No potential conflicts of interest were disclosed.
Références
J Virol. 2001 Jan;75(2):1061-4
pubmed: 11134321
Mol Ther. 2009 Aug;17(8):1465-72
pubmed: 19401673
J Virol. 2010 Feb;84(3):1563-73
pubmed: 19906910
Semin Immunol. 2020 Apr;48:101410
pubmed: 33011065
Cancer Res. 2004 Mar 15;64(6):2192-8
pubmed: 15026362
J Virol. 2006 Mar;80(5):2194-205
pubmed: 16474127
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10872-7
pubmed: 12960379
Curr Opin Immunol. 2017 Apr;45:43-51
pubmed: 28192720
Immunol Rev. 2010 Mar;234(1):90-104
pubmed: 20193014
J Immunother Cancer. 2018 Dec 4;6(1):139
pubmed: 30526667
Immunology. 2018 May;154(1):3-20
pubmed: 29313948
Trends Immunol. 2016 Dec;37(12):855-865
pubmed: 27793569
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
J Virol. 2011 Dec;85(23):12160-9
pubmed: 21917977
Methods Mol Biol. 2020;2058:237-248
pubmed: 31486042
Immunity. 2002 Jun;16(6):779-90
pubmed: 12121660
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Nat Immunol. 2011 Nov 20;13(1):51-7
pubmed: 22101728
Front Oncol. 2014 Apr 10;4:77
pubmed: 24782988
J Virol. 2003 Apr;77(8):4646-57
pubmed: 12663771
Cell Death Differ. 2004 Sep;11(9):953-61
pubmed: 15195071
Int J Mol Sci. 2018 Sep 18;19(9):
pubmed: 30231586
Annu Rev Immunol. 2013;31:563-604
pubmed: 23516985
Nat Rev Immunol. 2019 Feb;19(2):89-103
pubmed: 30464294
J Immunol Methods. 1999 Feb 1;223(1):77-92
pubmed: 10037236
Science. 1998 Dec 11;282(5396):2079-81
pubmed: 9851928
J Virol. 2009 Apr;83(7):2962-75
pubmed: 19144711
Nat Struct Mol Biol. 2016 Jun;23(6):513-521
pubmed: 27111888
Blood. 2012 Mar 29;119(13):3128-31
pubmed: 22310910
Vaccines (Basel). 2019 Jul 03;7(3):
pubmed: 31277325
Cancer Res. 2014 Jul 1;74(13):3567-78
pubmed: 24812275
Mol Ther Oncolytics. 2018 Jul 14;10:14-27
pubmed: 30073187
BioDrugs. 2019 Oct;33(5):485-501
pubmed: 31321623
Cell Death Dis. 2016 Nov 3;7(11):e2446
pubmed: 27809306
J Immunol. 2014 Nov 15;193(10):4914-4923
pubmed: 25288570
Cancer Cell. 2003 Oct;4(4):263-75
pubmed: 14585354
J Virol. 2014 May;88(9):4897-907
pubmed: 24554655
Eur J Immunol. 1997 Dec;27(12):3135-42
pubmed: 9464798
J Virol. 2013 Nov;87(21):11730-40
pubmed: 23986580
Int J Cancer. 2018 Oct 1;143(7):1786-1796
pubmed: 29696636
Curr Oncol. 2020 Apr;27(Suppl 2):S87-S97
pubmed: 32368178
Nat Immunol. 2018 Aug;19(8):885-897
pubmed: 30013147
Viruses. 2015 Dec 09;7(12):6506-25
pubmed: 26690204
J Virol. 2002 Aug;76(16):8011-8
pubmed: 12134006
J Immunol. 2014 Sep 1;193(5):2496-503
pubmed: 25070849
Mol Ther Oncolytics. 2016 Sep 28;3:16021
pubmed: 27738655
J Neuroimmunol. 2018 Sep 15;322:63-73
pubmed: 30049538
Front Immunol. 2018 Dec 03;9:2804
pubmed: 30559743
Int J Mol Sci. 2018 May 23;19(6):
pubmed: 29789517
J Innate Immun. 2018;10(2):131-144
pubmed: 29306950
Viruses. 2018 Mar 02;10(3):
pubmed: 29498639
Br J Cancer. 2019 Oct;121(8):647-658
pubmed: 31530903
J Gen Virol. 2017 Dec;98(12):2895-2911
pubmed: 29143726
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
PLoS Biol. 2014 Jan;12(1):e1001759
pubmed: 24409099
J Virol. 2011 Jun;85(11):5679-84
pubmed: 21450833
Nature. 2010 Jun 24;465(7301):1079-83
pubmed: 20577213
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7306-11
pubmed: 23589850
Nat Rev Immunol. 2017 Jun;17(6):349-362
pubmed: 28436425
Front Immunol. 2019 Dec 13;10:2759
pubmed: 31921102
J Exp Med. 2000 Nov 6;192(9):1249-60
pubmed: 11067874
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
J Exp Med. 2011 Nov 21;208(12):2367-74
pubmed: 22084408
J Virol. 2016 Oct 28;90(22):10050-10053
pubmed: 27605675
J Cell Biol. 2001 Oct 15;155(2):301-10
pubmed: 11604425
Virology. 2011 Mar 15;411(2):170-9
pubmed: 21185048
Blood. 2006 Jun 1;107(11):4417-23
pubmed: 16478884
Cancer Res. 1980 Mar;40(3):614-9
pubmed: 6162552
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023
J Immunol. 2003 Apr 15;170(8):3963-70
pubmed: 12682223